Cenix BioScience Signs Research Agreement with Boehringer Ingelheim for RNAi-Based Target Discovery
Cenix BioScience GmbH announced that it has signed a research agreement to support Boehringer Ingelheim in its ongoing efforts to discover novel therapeutic drug targets.
Cenix will apply its expertise in combining high throughput (HT) applications of RNAi-based gene silencing with high content phenotypic analyses in what will be a genome-scale screen using cultured human cells. Multi-parametric microscopy-based assays developed by Cenix using the Cellenger image analysis platform from Munich-based Definiens, will be used to complement proprietary assays developed at Boehringer Ingelheim, in order to generate detailed insights into the cellular functions and loss-of-function phenotypes of analyzed genes.
“We have long been looking forward to this opportunity to combine our own capabilities with those of our expert colleagues at Boehringer Ingelheim,” said Dr. Christophe Echeverri, CEO/CSO of Cenix. “We expect that the excellent complementarities between the two teams will deliver a particularly productive and cost-effective driver for these programs.”
Such RNAi datasets, now widely favored throughout the industry, offer a highly predictive and cost-effective basis for mining the human genome to discover and prioritize targets for therapeutic drug development in a wide range of disease fields.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Ectopic_pregnancy
BioMerieux Opens a Subsidiary in the Middle East, Continuing its International Growth

Merck and Japanese start-up launch collaboration - Both companies to accelerate development and manufacturing of viral vector-based gene therapy applications
Abbott and Enanta Present Positive 12-Week Results and 3-Day Resistance Data From Phase 2 Study of ABT-450/r for Treatment of Hepatitis C

Scientists stabilize HIV structure, design potential AIDS vaccine candidates
Propionyl-CoA
MIT researchers discover an unexpected twist in cancer metabolism - Cancer-cell quirk could be exploited to develop new drugs that starve tumors
New insights into latent HIV infections
